Insights

Global Manufacturing Partnership ImmunityBio recently partnered with the Serum Institute of India to manufacture BCG globally, indicating potential sales opportunities in international markets and partnerships with global manufacturers.

Clinical Trials Expansion The launch of Phase I/II trial of an endometrial cancer vaccine by ImmunityBio signifies a focus on expanding clinical trials, creating opportunities for collaboration with healthcare institutions and potential licensing of successful vaccines.

Financial Investment Boost Recent financing of $320 million by Oberland Capital showcases strong financial backing, hinting at potential opportunities for sales through increased research capabilities, product development, and market expansion.

Cutting-Edge Biotechnology ImmunityBio's innovative cell and immunotherapy products targeting cancer and infectious diseases reflect cutting-edge biotechnology offerings, presenting opportunities for partnerships, licensing agreements, and sales to healthcare providers and research institutions.

Market Expansion Investments made by ImmunityBio in assets like a plant for expansion suggest growth strategies, creating potential sales opportunities in supplying biotechnology equipment, facilities, and services to support their expansion endeavors.

ImmunityBio, Inc. Tech Stack

ImmunityBio, Inc. uses 8 technology products and services including Solium, IBM Cognos Analytics, Linkedin Insight Tag, and more. Explore ImmunityBio, Inc.'s tech stack below.

  • Solium
    Accounting And Finance
  • IBM Cognos Analytics
    Advanced Analytics And Data Science
  • Linkedin Insight Tag
    Analytics
  • Workday Recruiting
    Applicant Tracking Systems
  • SAS
    Business Intelligence
  • Microsoft Word
    Editors
  • Microsoft Excel
    Editors
  • WP Engine
    Platform As A Service

Media & News

ImmunityBio, Inc.'s Email Address Formats

ImmunityBio, Inc. uses at least 1 format(s):
ImmunityBio, Inc. Email FormatsExamplePercentage
First.Last@immunitybio.comJohn.Doe@immunitybio.com
96%
FLast@immunitybio.comJDoe@immunitybio.com
3%
First.Middle@immunitybio.comJohn.Michael@immunitybio.com
1%

Frequently Asked Questions

Where is ImmunityBio, Inc.'s headquarters located?

Minus sign iconPlus sign icon
ImmunityBio, Inc.'s main headquarters is located at 3530 John Hopkins Ct San Diego, CA 92121 US. The company has employees across 4 continents, including North AmericaEuropeAsia.

What is ImmunityBio, Inc.'s stock symbol?

Minus sign iconPlus sign icon
ImmunityBio, Inc. is a publicly traded company; the company's stock symbol is IBRX.

What is ImmunityBio, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
ImmunityBio, Inc.'s official website is immunitybio.com and has social profiles on LinkedIn.

How much revenue does ImmunityBio, Inc. generate?

Minus sign iconPlus sign icon
As of November 2024, ImmunityBio, Inc.'s annual revenue reached $300M.

What is ImmunityBio, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
ImmunityBio, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does ImmunityBio, Inc. have currently?

Minus sign iconPlus sign icon
As of November 2024, ImmunityBio, Inc. has approximately 579 employees across 4 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: R. A.Chief Technology Officer: E. D.Chief Financial Officer: D. S.. Explore ImmunityBio, Inc.'s employee directory with LeadIQ.

What industry does ImmunityBio, Inc. belong to?

Minus sign iconPlus sign icon
ImmunityBio, Inc. operates in the Biotechnology Research industry.

What technology does ImmunityBio, Inc. use?

Minus sign iconPlus sign icon
ImmunityBio, Inc.'s tech stack includes SoliumIBM Cognos AnalyticsLinkedin Insight TagWorkday RecruitingSASMicrosoft WordMicrosoft ExcelWP Engine.

What is ImmunityBio, Inc.'s email format?

Minus sign iconPlus sign icon
ImmunityBio, Inc.'s email format typically follows the pattern of . Find more ImmunityBio, Inc. email formats with LeadIQ.

How much funding has ImmunityBio, Inc. raised to date?

Minus sign iconPlus sign icon
As of November 2024, ImmunityBio, Inc. has raised $10M in funding. The last funding round occurred on Jan 02, 2024 for $10M.
ImmunityBio, Inc.

ImmunityBio, Inc.

Biotechnology ResearchCalifornia, United States501-1000 Employees

ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory.

Over the last two decades, our founder and Executive Chairman Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases.

"At ImmunityBio, we envision a day when we no longer fear cancer but are able to conquer it, thanks to the biological wonder that is the human immune system. Our scientists are working to develop remarkable new therapies that harness that inherent power by amplifying both branches of the immune system, attacking cancerous or infected cells today while building immunological memory for tomorrow. The goal: to reprogram the patient’s immune system and treat the host rather than just the disease." -Dr. Patrick Soon-Shiong, Executive Chairman

Section iconCompany Overview

Headquarters
3530 John Hopkins Ct San Diego, CA 92121 US
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
IBRX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
501-1000

Section iconFunding & Financials

  • $10M

    ImmunityBio, Inc. has raised a total of $10M of funding over 13 rounds. Their latest funding round was raised on Jan 02, 2024 in the amount of $10M.

  • $100M$1B

    ImmunityBio, Inc.'s revenue is in the range of $100M$1B

Section iconFunding & Financials

  • $10M

    ImmunityBio, Inc. has raised a total of $10M of funding over 13 rounds. Their latest funding round was raised on Jan 02, 2024 in the amount of $10M.

  • $100M$1B

    ImmunityBio, Inc.'s revenue is in the range of $100M$1B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.